^10th World Congress on Biomarkers & Clinical Research October 18-20, 2017 Baltimore, Maryland, USA

Dr. Búko has served as the Vice President of Human Metabolome Technologies-America (HMT-A) Biomarker discovery team since 2013, where he partners with biopharmaceutical companies to bring high resolution quantitative metabolomics profiling to pre-clinical and clinical studies. Prior to joining Human Metabolome Technologies, Dr. Búko was Senior Director Translational Medicine at Biogen for 10 years and Principal Investigator at Abbott labs for 18 years. He received his Ph.D. in Chemistry from the University of Virginia, with post-doctoral work for Bureau of Biologics and Biophysics at Food and Drug administration.

Dr. Búko’s career has focused primarily on omics solutions for biomarker and target discovery within the biopharma pipeline. Most of his work has been in immunology, infectious disease and neurology, however, at HMT-A he has widened his scope to many other therapeutic areas. While in biopharma Alex managed biomarker pipelines from pre-clinical to clinical studies using various protein and small molecule technologies to discovery and validate biomarkers for drug development and patient stratification. Dr. Búko’s areas of expertise include proteomics, lipidomics, metabolomics, protein assays and the statistical and biological pathway approaches required to combine omics data and generate prognostic and diagnostic algorithms.

Fred Baribaud holds a PhD from the University of Lausanne and has conducted postdoctoral studies at the University of Pennsylvania. He has worked at Incyte Corporation in a discovery role on target validation and as a compound team co-lead for small molecular inhibitors. For the past ten years, Fred has worked at Janssen R&D in Imunology Biomarkers on various inflammatory diseases. In his current role as Scientific Director he is focused on obtaining disease rational for targets and patient segmentation for inflammatory bowel diseases.

For the past ten years, Fred has worked at Janssen R&D in Imunology Biomarkers on various inflammatory diseases. In his current role as Scientific Director he is focused on obtaining disease rational for targets and patient segmentation for inflammatory bowel diseases.

Dr. Martin Burow is founder and owner of the DMB-Diagnostics GmbH and specialist for medical sales and marketing activities in Asia and Europe. Martin Burow has completed his PhD in Chemistry and Biochemistry at the University of Münster in 1993 and worked 3 years as a Post-doctoral fellow for the Ministry of International Trade and Industry at the National Institute of Materials and Chemical Research (NIMC) in Tsukuba, Japan. After his return to Germany, he started his career in the medical device industry and developed the Asian-Pacific markets for Brahms-Thermofisher in the field of medical diagnostics (thyroid, sepsis, prenatal and oncology). Later, he started his own company (DMB-Diagnostics GmbH) to introduce highly innovative diagnostics worldwide for better treatment standards for oncological patients.

biochemistry, diagnostics,regulatory

Professional experience in oncology circles, supported by multiple collaborations with major hospitals, allowed LOUIS CAZE to benefit from a reference fame as an Expert Support Care. First, Specialist lymphatic, muscular and circulatory LOUIS CAZE makes the total body approach his chosen field. It captures the benefits of physical-mental balance in the treatment of chronic diseases, and specializes in supportive care dedicated to cancer diseases. His collaboration with renowned organizations such as the Institute Gustave Roussy, was punctuated with exceptional professional and human experience. LOUIS CAZE is involved in implementing a comprehensive approach to cancer patient, in a real project of care that optimizes patient's quality of life, ensuring the different key aspects of health: the well physical and psychological, but also the entire social and family interactions. After these experiences, LOUIS CAZE work for the development of Support Care, including the management of pain and psychology.

LOUIS CAZE is involved in implementing a comprehensive approach to cancer patient, in a real project of care that optimizes patient's quality of life, ensuring the different key aspects of health: the well physical and psychological, but also the entire social and family interactions. After these experiences, LOUIS CAZE work for the development of Support Care, including the management of pain and psychology.

Dr. Pant received his M.A. and Ph.D. degrees in Physics from Agra University, Agra, India. His postdoctoral studies were conducted on the mechanisms of electron and ion transport in model membrane systems at the Department of Biophysics at Michigan State University. He joined the Laboratory of Neurobiology in the NIMH as a senior staff fellow in 1974 with Dr. Ichiji Tasaki where he studied the function of the axonal cytoskeleton in the squid giant axon. In 1979 he moved to the NIAAA extending his studies on the neuronal cytoskeleton and the effects of alcohol on its regulation. Dr. Pant moved to the NINDS, Laboratory of Neurochemistry in 1987 where he is presently chief of the section on Cytoskeleton Regulation. His laboratory is studying the mechanisms of topographic regulation of neuronal cytoskeleton proteins by post-translational modification, including the role of kinase cascades in normal brain and during neurodegeneration.

The major focus of this laboratory has been to study the mechanisms of topographic regulation of neuronal cytoskeletal proteins regulation by phosphorylation and neurodegeneration. In a normal physiological state, cytoskeletal proteins are phosphorylated extensively in the axonal compartment of a mature neuron. Although all the substrates, kinases, phosphatases and their regulators are synthesized in neuronal cell bodies, little or no cytoskeletal protein phosphorylation has been detected in the cell body compartment. Under a variety of neuropathological conditions, however, such as ALS, Alzheimers Disease, or Picks disease, hyperphosphorylation of these molecules has been found in abnormal aggregates within cell bodies, usually correlated with massive neuronal cell death. The mechanisms underlying these profound compartmental shifts in neuronal phosphorylation are not well understood.The normal physiological processes within neurons are controlled by signal transduction mechanisms that regulate the balance between protein kinase and protein phosphatase activities. We have shown that the most abundant and extensively phosphorylated motifs in the c-terminal domains (lys-ser-pro-, or KSP) are primarily phosphorylated by proline directed kinases, cdk5 and MAP kinases. Moreover, we have demonstrated that this phosphorylation is due to activation of the signal transduction cascade. Recently, we have focussed on the other part of this regulation, the protein phosphatases. The other project is to study the expression, regulation and role of neuronal Cdk5 in nerve cell function.Cdk5 is a unique multifunctional kinase. Unlike other cyclin-dependent kinases, it is expressed predominantly in post-mitotic neurons, its activity modulated by association with nervous system-specific propeins. Since its identification and characterization in our laboratory, we have been intensively studying its mechanisms of regulation and its role in nerve cell function.

Dr. Kamala K Maddali is currently Vice President, Biopharma Collaborations, Market Development and Companion Diagnostics at Cancer Genetics Inc, Rutherford, NJ. Cancer Genetics, Inc. (CGI) is a leader in the field of personalized medicine, offering diagnostic products and services that enable precision medicine in the field of oncology. Dr. Maddali holds a DVM Ph.D., in Pharmacology from University of Missouri-Columbia and a DVM Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India. Dr. Maddali brings over 10 years of extensive experience of global P&L scientific and commercial management of clinical biomarker and companion diagnostics (CDx) services covering personalized medicine strategy. Dr. Maddali brings a lot of strategic values from her previous roles at Quest Diagnostics, Quintiles and Merck Schering Plough in the arena of biomarkers and companion diagnostics.

Dr. Maddali brings over 10 years of extensive experience of global P&L scientific and commercial management of clinical biomarker and companion diagnostics (CDx) services covering personalized medicine strategy.

Dr. Srinivas Pentyala is the Director of Translational Research and Associate Professor of Anesthesiology in Stony Brook University Medical Center, NY, USA. He has joint appointments in the departments of Urology, Health Sciences, Physiology and Biophysics at SBUMC. Dr. Pentyala has 80 publications and several patents to his credit. Dr. Pentyala received several honors and awards not only for his role as a researcher but also as an educator. He is the founding director of several biotech and health care companies. He serves on the advisory board of several national and international biotech and health care companies, and research institutes.

He is the founding director of several biotech and health care companies. He serves on the advisory board of several national and international biotech and health care companies, and research institutes.

Dr. Luo is a member of the Divisions of Experimental Pathology, Molecular and Cellular Pathology and Anatomic Molecular Pathology. He is the Director of the High Throughput Genome Center at the Department of Pathology, University of Pittsburgh, involving collaboration of faculties from multiple departments. Dr. Luo been studying molecular pathology related to human malignancies in the last 23 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 13 years, Dr. Luo has been largely focusing on genetic and molecular mechanism of human prostate and hepatocellular carcinomas.

Currently, Dr. Luo's research interests involve identifying new tumor suppressor genes and tumor markers in several human malignancies such as prostate cancer, hepatocellular carcinoma, etc. Subsequently, we will direct our effort to evaluate the prognostic values of these genes and markers in making early diagnosis of prostate cancer and serving as drug targets for cancer prevention programs.

Xuemei is currently a Senior Principal Scientist in the Translational Molecular Biomarkers Department at Merck & Co., Inc. in Rahway, NJ. She received her Ph.D. in Chemistry from Columbia University and performed her postdoctoral research at Cold Spring Harbor Laboratory. Afterwards, Xuemei joined the Proteomics Department in Molecular Profiling at Merck in 2004. She led the biochemistry group focusing on sample preparation for LC-MS based proteomics profiling for biomarker discovery and new target identification. In 2012, Xuemei transitioned to clinical biomarker development. Currently, she leads the immunoassay group focusing on clinical biomarker assay development, validation, and implementation to support drug development clinical studies across all disease areas at Merck.

, she leads the immunoassay group focusing on clinical biomarker assay development, validation, and implementation to support drug development clinical studies across all disease areas at Merck.

Youhe Gao Professor Beijing Normal University. He received his MD from Peking Union Medical College, his Ph.D from University of Connecticut and postdoctoral training from Beth Israel Deaconess Medical Center, Harvard Medical School. He was the professor of Department of Pathophysiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences/ Peking Union Medical College from 2001-2014. His research interests include biomarker discovery in urine, urine biobanking, protein interaction methods and related bioinformatics.

His research interests include biomarker discovery in urine, urine biobanking, protein interaction methods and related bioinformatics.

Dr A-Lien Lu-Chang completed her PhD from University of North Carolina at Chepel Hill and postdoctoral studies from Duke University School of Medicine with Dr. Paul Modrich (Nobel laureate in Chemistry in 2015). She is the Professor of Biochemistry and Molecular Biology at University of Maryland Medical School and a member of University of Maryland Greenebaum Comprehensive Cancer Center. She has published more than 63 peer-reviewed papers in reputed journals, holds a potent, and has been serving as an editorial board members of four journals.

My laboratory is studying the interplays among DNA repair, DNA replication, cell cycle checkpoint, transcription, and chromatin remodeling. We investigate the impact of their coordination on telomere integrity and carcinogensis. Our work highlights potential targets that can be exploited clinically for cancer therapies.

Sergey Suchkov graduated from Astrakhan State Medical University and was awarded with MD. In 1985, Suchkov obtained his Ph.D. He is the PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences, Moscow, Russia. In 2001, Suchkov finished the PostDoc Research Fellowship Program and maintained his Doctor Degree at the National Institute of Immunology, Russia. From 1987 through 1989, Dr. Suchkov was a senior Researcher, Lab of Developmental Immunology, Koltzov Institute of Developmental Biology, USSR Academy of Sciences to deal to developmental immunology. From 1989 through 1995, Dr. Suchkov was being a Head of the Lab of Clinical Immunology and Immunobiotechnology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, Dr. Suchkov was being a Chairman of the Department for Clinical Immunology, Moscow Clinical Research Institute (MONIKI) and the Immunologist-in-Chief of the Moscow Regional Ministry of Health. At present, Dr Sergey Suchkov, MD, PhD, is Professor in Immunology, Department of Pathology, School for Pharmacy, I.M. Sechenov First Moscow State Medical University, Dean of the Department (Faculty) of The PPPM Development, and the First Vice-President of the University of World Business, Politics and Law and Secretary General, United Cultural Convention (UCC), Cambridge, UK.

Enzymology, biomarkers, cardiology, Immunology.

Dr. Qing Kay Li is an associate professor of pathology at the Johns Hopkins University School of Medicine. She has the American Board of Pathology certification in anatomic and clinical pathology, and subspecialty certification in cytopathology. Her areas of clinical expertise include surgical pathology and cytopathology. Dr. Li is also a faculty member and co-PI at the Johns Hopkins Biomarker Discovery Center.

Her research interests are focusing on the application of advanced cellular and molecular techniques to the field of cytopathology and cancer biology, particularly in the field of early detection of lung and prostate cancer.

Dr. Hoque is an Associate Professor of Otolaryngology-Head & Neck Surgery, Urology and Oncology at Johns Hopkins University School of Medicine. Dr. Hoque completed dental and oral surgery training at the Dhaka Dental College, Dhaka University, Bangladesh. He then moved to Japan for the completion of Ph.D degree, where he also completed Advanced Clinical Training in Oral and Maxillofacial Surgery and Oncology. After training in Japan, he worked in the Head and Neck Cancer Research Division as a Postdoctoral Fellow under the mentorship of Dr. David Sidransky. He joined as a faculty member in 2006 in the Department of Otolaryngology-Head and Neck Surgery. His research interests includes: a) To understand molecular biologic basis of head and neck, lung and genitourinary cancer b) To develop and validate genetic and epigenetic approach for early cancer diagnosis, cancer risk assessment and cancer prognosis and c) To identify molecular alterations due to environmental exposures such as active smoking, passive smoking and arsenic.

Develop and validate genetic and epigenetic approach for early cancer diagnosis, cancer risk assessment and cancer prognosis; Molecular biologic basis of head and neck, lung and genitourinary cancer.

B.Sc and M.Sc. degrees from Allahabad University and Ph.D. from Gujarat University. Areas of Specialization: Life Sciences, Radiation Biology, Biotechnology, Biophysics and chemistry. Research Guide for Ph.D. students in many Universities of India. Successfully guided 41 Ph.D. students. Presently guiding 08 students. Published more than 280 research papers and proceeding papers in National and International Journals. Delivered more than 300 invited talks in Symposia and Conferences. Currently the Vice Chancellor of Nehru Gram Bharati University, Allahabad, India. Served as Head, Radiation Biology and Health Science Division and Senior Scientific Officer of Bhabha Atomic Research Center, Department of Atomic Energy, and Government of India. Chairman, Standing Selection Committee, Member, Trombay Scientific Council, BARC, Member, Health, Safety & Biomedical Group Board, Member, Committee of Atomic Energy Commission on Health and Environment Aspects of Uranium Mining at Jaduguda, Member, Core Expert Group on Chemical Disaster and Nuclear Disaster Management of National Disaster Management Authotrity of India (NDMA). Served as Chancellor's Nominee in Selection Committees of Padmashri Dr. D.Y. Patil Deemed University; Mumbai and West Bengal University of Technology, Kolkata and served as Expert on Selection Committees of IITs and several Universities in India.B.Sc and M.Sc. degrees from Allahabad University and Ph.D. from Gujarat University. Areas of Specialization: Life Sciences, Radiation Biology, Biotechnology, Biophysics and chemistry. Research Guide for Ph.D. students in many Universities of India. Successfully guided 41 Ph.D. students. Presently guiding 08 students. Published more than 280 research papers and proceeding papers in National and International Journals. Delivered more than 300 invited talks in Symposia and Conferences. Currently the Vice Chancellor of Nehru Gram Bharati University, Allahabad, India. Served as Head, Radiation Biology and Health Science Division and Senior Scientific Officer of Bhabha Atomic Research Center, Department of Atomic Energy, and Government of India. Chairman, Standing Selection Committee, Member, Trombay Scientific Council, BARC, Member, Health, Safety & Biomedical Group Board, Member, Committee of Atomic Energy Commission on Health and Environment Aspects of Uranium Mining at Jaduguda, Member, Core Expert Group on Chemical Disaster and Nuclear Disaster Management of National Disaster Management Authotrity of India (NDMA). Served as Chancellor's Nominee in Selection Committees of Padmashri Dr. D.Y. Patil Deemed University; Mumbai and West Bengal University of Technology, Kolkata and served as Expert on Selection Committees of IITs and several Universities in India.

Radiation Research, Biomarkers, Biophysics, Biotechnology

Dr. Suzuki worked in Research and Development Center, Hitachi Medical Co, Japan, from 1993 to 1997. From 1997 to 2001, he worked in Faculty of Information Science and Technology, Aichi Prefectural University, Japan, as a faculty member. In 2001, he joined Department of Radiology, University of Chicago, as Research Associate. He was promoted to Assistant Professor of Radiology, Graduate Program in Medical Physics, and Cancer Research Center in 2006. Since 2014, he has been Associate Professor in Medical Imaging Research Center and Department of Electric and Computer Engineering, Illinois Institute of Technology.

His research interests include computational intelligence and machine learning in medical imaging, computer-aided detection and diagnosis, and medical image processing and analysis. He published more than 230 papers (including 95 peer-reviewed journal papers) and 75 refereed abstracts.

Zeliha Selamoglu trained at the Department of Biology, Faculty of Arts and Science, Inonu University, Malatya, Turkey (Ph.D, 2005). She is at the Department of Biotechnology, Faculty of Arts and Science, Omer Halisdemir University, Nigde, Turkey at the now (Full. Prof., 2015). Her research interests include tyrosine tydroxylase activity, oxidative stress, antioxidants, selenium, bee products such as propolis and also natural products. Her current research concerns the antioxidant activity, in vivo oxidative stress by environmental chemicals and health risk assessment of environmental chemicals. The studing of heavy metals which environmental contaminants, toxic agents and trace metals which have some metabolic and environmental effects are important try fields. She has researched antihypertensive effects of organoselenium, bee products such as CAPE, pollen and propolis which played an important role in supression of oxidative stress, too. She has also researched biological activities of natural protective agents which is very important at detoxification of toxic chemicals. Besides, that the investigation of natural antioxidants which has metabolic significance and effects againts oxidative stress and hypertension in vivo. In addition to, synthetic antioxidants has been included her interested area. She has got two membership. These name are “Society for Experimental Biology and Medicine” and “European association for cancer research”. She has got reviewership some journals. Some of these: Antioxidants & Redox Signaling, Ecotoxicology and Environmental Safety, Iranian Journal of Fisheries Science, Fish Physiology and Biochemistry, Fresenius Environmental Bulletin, Biological Trace Element Research, Journal of Food Science, International Journal of Environmental Engineering Science, International Journal of Medicine and Medical Sciences, Experimental and Molecular Pathology, European Journal of Medicinal Chemistry, Current Drug Delivery, Asian Journal of Biochemistry, International Journal of Biological Chemistry, Journal of Pharmacology and Toxicology.

Her current research concerns the antioxidant activity, in vivo oxidative stress by environmental chemicals and health risk assessment of environmental chemicals. The studing of heavy metals which environmental contaminants, toxic agents and trace metals which have some metabolic and environmental effects are important try fields.

Zhigang Kang has completed his PhD from University of Helsinki, Finland and Post-doctoral studies from NIMH, NIH. He is a Research Scientist in Molecular Target Core, Genetics Branch, Center for Cancer Research, National Cancer Institute and an employee of Basic Science Program, Leidos Biomedical Research, Inc., Frederick. He has been working in the field of cancer biomarkers for the past 7 years. His research interests focus on the detection of invasive tumor biomarkers include circulating tumor cell (CTC), cell free circulating tumor DNA and clinical relevance protein markers from peripheral blood of patients with various types of tumors.

His research interests focus on the detection of invasive tumor biomarkers include circulating tumor cell (CTC), cell free circulating tumor DNA and clinical relevance protein markers from peripheral blood of patients with various types of tumors.

Zhigang Kang has completed his PhD from University of Helsinki, Finland and Post-doctoral studies from NIMH, NIH. He is a Research Scientist in Molecular Target Core, Genetics Branch, Center for Cancer Research, National Cancer Institute and an employee of Basic Science Program, Leidos Biomedical Research, Inc., Frederick. He has been working in the field of cancer biomarkers for the past 7 years. His research interests focus on the detection of invasive tumor biomarkers include circulating tumor cell (CTC), cell free circulating tumor DNA and clinical relevance protein markers from peripheral blood of patients with various types of tumors.

His research interests focus on the detection of invasive tumor biomarkers include circulating tumor cell (CTC), cell free circulating tumor DNA and clinical relevance protein markers from peripheral blood of patients with various types of tumors.

Hem D. Shukla is Research Scientist in Department of Pharmaceutical Sciences at University of Maryland and adjunct Professor of Genomics in Notre Dame of Maryland University. He has also worked as Research Faculty in Department of Biology at Johns Hopkins University. Dr. Shukla has worked on proteomic analysis of oxidative stress response in BxPC-3 pancreatic cell lines and identification of biomarkers for early detection of pancreatic cancer. He has worked on “The Nrf2 mediated antioxidant defense against oxidative stress in pancreatic cancer cell lines and targets for therapeutic intervention”. He has shown elevated level of Nrf2 transcriptional factor in pancreatic cancer cell lines under oxidative stress which is phosphorylated by protein kinase C and affects phosphatidylinositol 3-kinase and MAP kinase pathways. After phosphorylation, Nrf2 translocates to the nucleus, binds AREs and transactivates detoxifying enzymes and antioxidant enzymes, such as glutathione S-transferase, and superoxide dismutase. The IPA analysis has suggested a potential role of Nrf2 under oxidative stress conditions.

Proteomic analysis of oxidative stress response in BxPC-3 pancreatic cell lines Identification of biomarkers for pancreatic cancer Nrf2 mediated antioxidant defense against oxidative stress in pancreatic cancer cell lines.

David I Smith completed his Ph.D. at the age of 23 years from the University of Wisconsin in Madison and then did post-doctoral studies at the University of California in Irvine. Since 1996 he has been a Professor at the Mayo Clinic in the Department of Laboratory Medicine and Pathology. He is also the Chairman of the Technology Assessment Group for the Center for Individualized Medicine at the Mayo Clinic. His laboratory studies the common fragile sites and the role that these regions of instability play in the development of cancer. His group also studies the different ways that HPV can contribute to the development of different cancers. He has published over 200 papers in reputed journals and serves on the Editorial Board of a number of journals.

His group also studies the different ways that HPV can contribute to the development of different cancers. He has published over 200 papers in reputed journals and serves on the Editorial Board of a number of journals.

Dimitrios H. Roukos is currently working as Founding Director, Centre for Biosystems & Synthetic Genomic Network Medicine - CBS. GenNetMed Ioannina University- Ioannina, Greece. He is also Leader at Translational Research, European Network of Excellence (EUNE) for Gastric Cancer (since 2006) and affiliated to Department of Surgery, Ioannina University Hospital , Ioannina , Greece (since 1990). Dr. D. Roukos has graduated from Athens University School of Medicine, Greece. He underwent specialist training in surgery at the J.W.Goethe-University Hospital in Frankfurt a.M., Germany where received his Doctorate (Dr.med). He moved back to Greece and since 1990 works at the Ioannina University School of Medicine.

Genetics, Pathology, Biomarkers, Systems biology & and cancer networks